Xperi (NYSE:XPER) and Black Titan (NASDAQ:BTTC) Head to Head Analysis

Black Titan (NASDAQ:BTTC) and Xperi (NYSE:XPER) are both small-cap services companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, profitability, earnings and valuation.

Earnings and Valuation

This table compares Black Titan and Xperi”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Black Titan	$180,000.00	75.75	-$4.71 million	($2.95)	-0.51
Xperi	$448.11 million	0.62	-$56.34 million	($1.23)	-4.78

Black Titan has higher earnings, but lower revenue than Xperi. Xperi is trading at a lower price-to-earnings ratio than Black Titan, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

94.3% of Xperi shares are held by institutional investors. 53.7% of Black Titan shares are held by company insiders. Comparatively, 3.2% of Xperi shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Profitability

This table compares Black Titan and Xperi’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Black Titan	N/A	-108.60%	-95.64%
Xperi	-12.57%	-0.73%	-0.49%

Volatility & Risk

Black Titan has a beta of 1.4, meaning that its share price is 40% more volatile than the S&P 500. Comparatively, Xperi has a beta of 1.24, meaning that its share price is 24% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Black Titan and Xperi, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Black Titan	1	0	0	0	1.00
Xperi	2	0	0	0	1.00

Summary

Black Titan beats Xperi on 6 of the 11 factors compared between the two stocks.

About Black Titan

Titan Pharmaceuticals, Inc. is a biopharmaceutical company developingproprietary therapeutics for the treatment of central nervous system disorders, cancer, and other serious and life threatening diseases. In the central nervous system arena, the company is developing iloperidone, which is clinical testing for schizophrenia through a licensing and development agreement with Novartis Pharma AG. Novartis has tradenamed the product Zomaril.

About Xperi

Xperi Holding Corporation, together with its subsidiaries, operates as a consumer and entertainment product/solutions licensing company worldwide. It operates through two segments, Product, and Intellectual Property Licensing. The company invents, develops, and delivers various technologies. It licenses audio, digital radio, imaging, edge-based machine learning, and multi-channel video user experience solutions to consumer electronics customers, automotive manufacturers, or supply chain partners. The company also provides licensing to multichannel video programming distributors, OTT video service providers, consumer electronics manufacturers, social media, and other new media companies in media industry; and memory, sensors, RF component, and foundry companies in semiconductor industry. It provides its technologies under the DTS, HD Radio, IMAX Enhanced, Invensas, TiVo, and Perceive brands. The company is headquartered in San Jose, California.